ArticleFrontiers in immunology2024

Prognostic impact of clinical factors for immune checkpoint inhibitor with or without chemotherapy in older patients with non-small cell lung cancer and PD-L1 TPS ≥ 50.

Shota Takei et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.